Compare SAFE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | MPLT |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1999 | N/A |
| Metric | SAFE | MPLT |
|---|---|---|
| Price | $14.62 | $30.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $19.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 355.3K | 272.1K |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $37.93 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $12.24 |
| 52 Week High | $17.16 | $33.28 |
| Indicator | SAFE | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 59.25 |
| Support Level | $14.45 | $26.70 |
| Resistance Level | $16.31 | $32.68 |
| Average True Range (ATR) | 0.44 | 2.39 |
| MACD | -0.09 | -0.31 |
| Stochastic Oscillator | 22.76 | 80.49 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.